Singapore, March 17 -- China & US based HarbourBioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in immunology and oncology, has announced the launch of Elance Therapeutics.

Harnessing Harbour BioMed's proprietary HCAb-based bispecific antibody technology, Elance aims to develop innovative therapies addressing key challenges in current obesity treatment, including muscle preservation and long-term efficacy.

Obesity affects nearly one billion people worldwide and is associated with serious health complications, yet current treatments remain inadequate for many patients. Despite recent advancements, challenges such as limited efficacy, lean mass loss, an...